Aclidinium bromide/formoterol fumarate fixed-dose combination for the treatment of chronic obstructive pulmonary disease

Expert Opinion on Pharmacotherapy

Volumn 14, Issue 6, 2013, Pages 775-781

  Cazzola, Mario ^a,b,d   Rogliani, Paola ^a   Matera, Maria Gabriella ^c  

^a UNIVERSITY OF ROME TOR VERGATA   (Italy)

^b IRCCS SAN RAFFAELE PISANA   (Italy)

^c SECOND UNIVERSITY OF NAPLES   (Italy)

^d UNIVERSITY OF ROME TOR VERGATA   (Italy)

Author keywords

Aclidinium bromide; COPD; Formoterol fumarate; LABA LAMA fixed dose combination therapy

Indexed keywords

ACLIDINIUM BROMIDE; ACLIDINIUM BROMIDE PLUS FORMOTEROL FUMARATE; AEROLIZER; BETA ADRENERGIC RECEPTOR STIMULATING AGENT; BRONCHODILATING AGENT; CORTICOSTEROID; FORMOTEROL; FORMOTEROL FUMARATE; GENUAIR; GLYCOPYRRONIUM BROMIDE; INDACATEROL; IPRATROPIUM BROMIDE; LAS 40464; MUSCARINIC RECEPTOR BLOCKING AGENT; OLODATEROL; PLACEBO; RESPIRATORY TRACT AGENT; SALMETEROL; TIOTROPIUM BROMIDE; UMECLIDINIUM; UNCLASSIFIED DRUG; VILANTEROL;

ARTICLE; CHRONIC OBSTRUCTIVE LUNG DISEASE; CORTICOSTEROID THERAPY; COST EFFECTIVENESS ANALYSIS; DRUG APPROVAL; DRUG CONTROL; DRUG EFFICACY; HUMAN; MONOTHERAPY; QUALITY ADJUSTED LIFE YEAR; QUALITY OF LIFE; RETROSPECTIVE STUDY;

BRONCHODILATOR AGENTS; DRUG COMBINATIONS; DRUG DESIGN; ETHANOLAMINES; HUMANS; MUSCARINIC ANTAGONISTS; PULMONARY DISEASE, CHRONIC OBSTRUCTIVE; TROPANES;

EID: 84875128903     PISSN: 14656566     EISSN: 17447666     Source Type: Journal    
DOI: 10.1517/14656566.2013.776539     Document Type: Article

References (34)

1. O'Reilly J, Jones MM, Parnham J, et al. Management of stable chronic obstructive pulmonary disease in primary and secondary care: Summary of updated. NICE guidance. BMJ 2010;340:c3134
2. Global Initiative for Chronic Obstructive Lung Disease (GOLD). Global strategy for the diagnosis, management, and prevention of chronic obstructive lung disease. Revised 2011. Available from: Http://www.goldcopd.com [Last accessed 23 December 2012]
3. Rodrigo GJ, Plaza V, Castro-Rodriguez JA. Comparison of three combined pharmacological approaches with tiotropium monotherapy in stable moderate to severe COPD: A systematic review. Pulm Pharmacol Ther 2012;25:40-7
4. Cazzola M, Molimard M. The scientific rationale for combining long-acting beta2-agonists and muscarinic antagonist in COPD. Pulm Pharmacol Ther 2010;23:257-67
5. Cazzola M, Calzetta L, Matera MG. Beta2-adrenoceptor agonists: Current and future direction. Br J Pharmacol 2011;163:4-17
6. Cazzola M, Page CP, Calzetta L, Matera MG. Pharmacology and therapeutics of bronchodilators. Pharmacol Rev 2012;64:450-504
7. Yu AP, Guerin A, de Leon DP, et al. Clinical and economic outcomes of multiple versus single long-acting inhalers in COPD. Respir Med 2011;105:1861-71
8. Yu AP, Guerin A, Ponce de Leon D, et al. Therapy persistence and adherence in patients with chronic obstructive pulmonary disease: Multiple versus single long-acting maintenance inhalers. J Med Econ 2011;14:486-96
9. Cazzola M, Segreti A, Bettoncelli G, et al. Change in asthma and COPD prescribing by Italian general practitioners between 2006 and 2008. Prim Care Respir J 2011;20:291-8
10. Rutten-van Molken MP, Goossens LM. Cost effectiveness of pharmacological maintenance treatment for chronic obstructive pulmonary disease: A review of the evidence and methodological issues. Pharmacoeconomics 2012;30:271-302
11. Kozma CM, Paris AL, Plauschinat CA, et al. Comparison of resource use by COPD patients on inhaled therapies with long-acting bronchodilators: A database study. BMC Pulm Med 2011;11:61
12. Anonymous. Global Markets for Asthma and COPD Drugs to hit $47 Billion in 2017. Available from: Www.marketwatch. com/story/global-markets-for- asthmacopd-drugs-to-hit-47-billion-in-2017-2012-08-21 [Last accessed 7 October, 2012]
13. Kessler R, Partridge MR, Miravitlles M, et al. Symptom variability in patients with severe COPD: A pan-European cross-sectional study. Eur Respir J 2011;37:264-72
14. Cazzola M, Tashkin DP. Combination of formoterol and tiotropium in the treatment of COPD: Effects on lung function. COPD 2009;6:404-15
15. Matera MG, Page CP, Cazzola M. Novel bronchodilators for the treatment of chronic obstructive pulmonary disease. Trends Pharmacol Sci 2011;32:495-506
16. Sentellas S, Ramos I, Alberti J, et al. Aclidinium bromide, a new, long-acting, inhaled muscarinic antagonist: In vitro plasma inactivation and pharmacological activity of its main metabolites. Eur J Pharm Sci 2010;39:283-90
17. Jansat JM, Lamarca R, de Miquel G, et al. Safety and pharmacokinetics of multiple doses of aclidinium bromide, a novel long-acting muscarinic antagonist for the treatment of chronic obstructive pulmonary disease, in healthy participants. J Clin Pharmacol 2009;49:1239-46
18. Jones PW, Singh D, Bateman ED, et al. Efficacy and safety of twice-daily aclidinium bromide in COPD patients: The ATTAIN study. Eur Respir J 2012;40:830-6
19. Cazzola M, Rogliani P, Segreti A, Matera MG. An update on bronchodilators in Phase I and II clinical trials. Expert Opin Investig Drugs 2012;21:1489-50
20. Anonymous. Almirall starts Phase III for aclidinium and formoterol in COPD. Available from: Www.almirall.com/webcorp2/contentFiles/1596/en/AB +For-Phase-III-press-release-final.pdf [Last accessed 7 October, 2012]
21. Sliwinski P, Perng D-W, Chuchalin A, Jones PW. Efficacy and safety of once-daily aclidinium bromide 200 mug in combination with formoterol in patients with COPD (abstract). Thorax 2010;65:A136
22. Magnussen H, Watz H, Kretschmar G, et al. Pharmakokinetik, Sicherheit und Aktivitat von formoterol verabreicht uber den Genuair Inhalator- mit und ohne Aclidinium-Bromid (Abstract). Pneumologie 2011;65:V446
23. UK Medicines Information (UKMI). New Drugs Online Report for aclidinium bromide + formoterol fumarate. Available from: Www.ukmi.nhs. uk/applications/ndo/record-view-open. asp?newDrugID=5527 [Last accessed 7 October, 2012]
24. Cazzola M, Matera MG, Donner CF. Inhaled beta2-adrenoceptor agonists: Cardiovascular safety in patients with obstructive lung disease. Drugs 2005;65:1595-610
25. Cazzola M, Calzetta L, Matera MG. The cardiovascular risk of tiotropium: Is it real? Expert Opin Drug Saf 2010;9:783-92
26. Gavalda A, Vinyals M, Aubets J, Gra J. Effect of formoterol alone and in combination with aclidinium on electrocardiograms in dogs (abstract). ERS Annual Congress, Vienna 2012. Available from: Www.ers-education.org/pages/default. aspx? id=2828&idBrowse=120660&det=1 [Last accessed 7 October, 2012]
27. Cazzola M, Matera MG. The effective treatment of COPD: Anticholinergics and what else? Drug Discov Today Ther Strateg 2006;3:277-86
28. Qaseem A, Wilt TJ, Weinberger SE, et al. Diagnosis and management of stable chronic obstructive pulmonary disease: A clinical practice guideline update from the American College of Physicians, American College of Chest Physicians, American Thoracic Society, and European Respiratory Society. Ann Intern Med 2011;155:179-91
29. Puffer A. U.S. physician and payer attitudes to novel and me-too fixed dose combination inhalers for asthma and chronic obstructive pulmonary disease. Available from: Http://decisionresources. com/Products-and-Services/Report? r=pforus0712 [Last accessed 7 October 2012]
30. Cazzola M, Brusasco V, Centanni S, et al. Project PriMo: Sharing principles and practices of bronchodilator therapy monitoring in COPD: A consensus initiative for optimizing therapeutic appropriateness among Italian specialists. Pulm Pharmacol Ther 2012;doi: 10.1016/j.pupt.2012.10.010
31. Agusti A, Hedner J, Marin JM, et al. Night-time symptoms: A forgotten dimension of COPD. Eur Respir Rev 2011;20:183-94
32. Miles MC, Donohue JF, Ohar JA. Optimum bronchodilator combinations in chronic obstructive pulmonary disease: What is the current evidence? Drugs 2012;72:301-8
33. van der Molen T, Cazzola M. Beyond lung function in COPD management: Effectiveness of LABA/LAMA combination therapy on patient-centred outcomes. Prim Care Respir J 2012;21:101-8
34. Cazzola M, MacNee W, Martinez FJ, et al. Outcomes for COPD pharmacological trials: From lung function to biomarkers. Eur Respir J 2008;31:416-69